Stability and enzymatic studies with omeprazole: hydroxypropyl-β-cyclodextrin

The original publication is available at www.springerlink.com. A publicação original está disponível em www.springerlink.comOmeprazole (OME) exhibits low stability to light, heat and humidity. In stress conditions OME stability should improve under inclusion complex form with hydroxypropyl-b-cyclodextrin (HPbCD). Stability of OME, its physical mixture (PM) with HPbCD and OME:HPbCD inclusion complex was assessed during 60 days. The inclusion complexes were prepared by kneading and freezedrying techniques and characterized by differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy (FTIR). A molecular modelling was also held to predict the most probable tridimensional conformation of inclusion complex OME:HPbCD. The inhibitory activity of free and complexed OME on selected enzymes, namely, papain (protease model of the proton pump) and acetylcholinesterase (enzyme present in cholinergic neurons and also involved in Alzheimer’s disease) was compared. The results obtained show that HPbCD do not protect against OME degradation, in any prepared powder, in the presence of light, heat and humidity. This may indicate that the reactive group of OME is not included in the HPbCD cavity. This fact is supported by molecular modelling data, which demonstrated that 2-pyridylmethyl group of OME is not included into the cyclodextrin cavity. In relation to enzymatic assays it was observed that free OME and OME in the binary systems showed identical inhibitory activity on papain and acethylcolinesterase, concluding that HPbCD do not affect OME activity on these two enzymes

Determination of the melting temperature, heat of fusion, and purity analysis of different samples of zidovudine (AZT) using DSC

The determination of chemical purity, melting range, and variation of enthalpy in the process of characterizing medicines is one of the principal requirements evaluated in quality control of the pharmaceutical industry. In this study, the method of purity determination using DSC was outlined, as well as the application of this technique for the evaluation of commercial samples of zidovudine (AZT) (raw material) supplied by different laboratories. To this end, samples from six different laboratories (A, B, C, D, E, and F) and the standard reference (R) from the United States Pharmacopeia (USP) were analyzed. The DSC curves were obtained in the temperature range of 25 to 200 ºC under the dynamic atmosphere of N2 (50 mL min-1), heating rate of β=2 ºC min-1, using an Al capsule containing approximately 2 mg of sample material. The results demonstrated that the standard reference presented a proportion of 99.83% whereas the AZT samples presented a variation ranging from 97.59 to 99.54%. In addition, the standard reference was found to present a temperature of onset of melting point of 122.80 °C. Regarding the samples of active agents provided by the different laboratories, a variation ranging from 118.70 to 122.87 °C was measured. In terms of ΔHm, the samples presented an average value of 31.12 kJ mol-1._________________________________________________________________________________________ RESUMO: A determinação da pureza química, a faixa de fusão e a variação de entalpia envolvida no processo de caracterização de fármacos é um dos principais requisitos avaliados no controle de qualidade em indústrias farmacêuticas. Neste trabalho é feita uma breve abordagem sobre o método de determinação de pureza utilizando DSC, assim como a aplicação desta técnica para avaliação de amostras comerciais de zidovudina (AZT) (matéria-prima) fornecida por diferentes laboratórios. Para tal, foram analisadas amostras de seis diferentes laboratórios (A,B,C,D,E e F) e a substância química de referência (R) da United States Pharmacopeia (USP). As curvas DSC foram obtidas na faixa de temperatura entre 25 a 200 ºC, sob atmosfera dinâmica de N2 (50 mL min-1), β=2 ºC min-1, utilizando cápsula de Al contendo aproximadamente 2 mg de amostra. De acordo com os resultados, pode-se observar que a substância química de referência apresentou teor igual a 99,83% e que as amostras de AZT apresentaram uma faixa de variação entre 97,59 e 99,54%. Pode-se verificar, ainda, que a substância química de referência apresentou uma temperatura onset de fusão igual a 122,80 °C. Para as amostras dos princípios ativos fornecidos pelos diferentes laboratórios, pode-se verificar uma faixa de variação entre 118,70 e 122,87 °C. No que se refere ao ΔHm, as amostras apresentaram valor médio de 31,12 kJ.mol-1

Design, Synthesis And Biological Evaluation Of Hybrid Bioisoster Derivatives Of N-acylhydrazone And Furoxan Groups With Potential And Selective Anti-trypanosoma Cruzi Activity

Hybrid bioisoster derivatives from N-acylhydrazones and furoxan groups were designed with the objective of obtaining at least a dual mechanism of action: cruzain inhibition and nitric oxide (NO) releasing activity. Fifteen designed compounds were synthesized varying the substitution in N-acylhydrazone and in furoxan group as well. They had its anti-Trypanosoma cruzi activity in amastigotes forms, NO releasing potential and inhibitory cruzain activity evaluated. The two most active compounds (6, 14) both in the parasite amastigotes and in the enzyme contain the nitro group in para position of the aromatic ring. The permeability screening in Caco-2 cell and cytotoxicity assay in human cells were performed for those most active compounds and both showed to be less cytotoxic than the reference drug, benznidazole. Compound 6 was the most promising, since besides activity it showed good permeability and selectivity index, higher than the reference drug. Thereby the compound 6 was considered as a possible candidate for additional studies. © 2014 Elsevier Masson SAS. All rights reserved.82418425Coura, J.R., Dias, J.C.P., Epidemiology, control and surveillance of Chagas disease - 100 years after its discovery (2009) Mem. Inst. Oswaldo Cruz, 104, pp. 31-40Anis, R.J., Anis, R., Marin-Neto, J.A., Chagas disease (2010) Lancet, 375, pp. 1388-1402(2013), http://www.who.int/mediacentre/factsheets/fs340/en/index.html, World Health Organization, WHOGascon, J., Bern, C., Pinazo, M.J., Chagas disease in Spain, the United States and other non-endemic countries (2010) Acta Trop., 115, pp. 22-27Nunes, M.C.P., Dones, W., Montillo, C.A., Encina, J.J., Ribeiro, A.L., Chagas disease: An overview of clinical and epidemiological aspects (2013) J. A. Coll. Cardiol., 62, pp. 767-776Dias, L.C., Dessoy, M.A., Silva, J.N.S., Thiemann, O.H., Oliva, G., Andricopulo, A.D., Quimioterapia da doença de Chagas: Estado da arte e perspectivas no desenvolvimento de novos fármacos (2009) Quim. Nova, 32, pp. 2444-2457Alves, R.M., Thomaz, R.P., Almeida, E.A., Wanderley, J.S., Guariento, M.E., Chagas disease and egeing: The coexistence of other chronic disease with Chagas disease in elderly patients (2009) Rev. Soc. Bras. Med. Trop., 42, pp. 622-628Barreiro, E.J., Fraga, C.A.M., (2008) Química Medicinal: As Bases Moleculares da Ação Dos Fármacos, pp. 271-277. , second ed. Artmed Porto Alegre 343-345Lima, L.M., Barreiro, E.J., Bioisosterism: A useful strategy for molecular modification and drug design (2005) Curr. Med. Chem., 12, pp. 23-49Viegas-Junior, C., Danuello, A., Bolzani, V.S., Barreiro, E.J., Fraga, C.A.M., Molecular hybridization: A useful tool in the design of new drug prototypes (2007) Curr. Med. Chem., 14, pp. 1829-1852Serafim, R.A.M., Primi, M.C., Trossini, G.H.G., Ferreira, E.I., Nitric oxide: State of the art in drug design (2012) Curr. Med. Chem., 19, pp. 385-405Cerecetto, H., González, M., Anti-T. Cruzi agents: Our experience in the evaluation of more than five hundred compounds (2008) Mini-Rev. Med. Chem., 8, pp. 1355-1383Silva, J.J.N., Guedes, P.M.M., Zottis, A., Balliano, T.L., Silva, F.O.N., Lopes, L.G.F., Ellena, J., Silva, J.S., Novel ruthenium complexesas potential drugs for Chagas's disease: Enzyme inhibition and in vitro/in vivo trypanocidal activity (2010) Br. J. Pharmacol., 160, pp. 260-269Brunet, L.R., Nitric oxide in parasitic infections (2001) Int. Immunopharmacol., 1, pp. 1457-1467Romeiro, N.C., Aguirre, G., Hernandez, P., Gomzalez, M., Cerecetto, H., Aldana, I., Perez-Silanes, S., Lima, L.M., Synthesis, trypanocidal activity and docking studies of novel quinaxoline-N-acylhydrazones, designed as cruzain inhibitors candidates (2009) Bioorg. Med. Chem., 17, pp. 641-652Moreira, D.R.M., Leite, A.C.L., Santos, R.R., Soares, M.B.P., Approaches for the development of new anti-Trypanosoma cruzi agents (2009) Curr. Drugs Targets, 10, pp. 212-231McGrath, M.E., Eakin, A.E., Engel, J.C., McKerrow, J.H., Craik, C.S., Fletterick, R.J., The crystal structure of cruzain: A therapeutic target for Chagas' disease (1995) J. Mol. Biol., 247, pp. 251-259Judice, W.A.S., Cezari, M.H.S., Lima, A.P.C.A., Scharfstein, J., Chagas, J.R., Tersariol, I.L.S., Juliano, M.A., Juliano, L., Comparison of the specificity, stability and individual rate constants with respective activation parameters for the peptidase activity of cruzipain and its recombinant form, cruzain, from Trypanosoma cruzi (2001) Eur. J. Biochem., 268, pp. 6578-6586Wilkinson, S.R., Bot, C., Kelly, J.M., Hall, B.S., Trypanocidal activity of nitroaromatic prodrugs: Current treatments and future perspectives (2011) Curr. Med. Chem., 11, pp. 2072-2084(1998) MarvinView 5.4.0. - Free License, , ChemAxon LtdHernandez, P., Rojas, R., Gilman, R.H., Sauvain, M., Lima, L.M., Barreiro, E.J., Gonzalez, M., Cerecetto, H., Hybrid furoxanyl N-acylhydrazone derivatives as hits for the development of neglected diseases drug candidates (2013) Eur. J. Med. Chem., 59, pp. 64-74Storpirtis, S., Gonçalves, J.E., Chiann, C., Gai, M.N., Biofarmacotécnica-série ciências farmacêuticas (2009) Guanab. Koogan, pp. 204-211Souza, J., Benet, L.Z., Huang, Y., Storpirtis, S., Comparison of bidirectional Lamavudine and Zidovudine transport using MDCK, MDCK-MDR1, and Caco-2 cell monolayers (2009) J. Pharm. Sci., 98, pp. 4413-4419Chavda, H.V., Patel, C.N., Anand, I.S., Biopharmaceutical classification system (2010) Syst. Rev. Pharm., 1, pp. 62-69Huber, P.C., Maruiama, C.H., Almeida, W.P., Glicoproteína-P, resistência a múltiplas drogas (MDR) e relação estrutura-atividade de moduladores (2010) Quim. Nova, 33, pp. 2148-2154Fruttero, R., Ferrarotti, B., Serafino, A., Stiloa, D., Gasco, A., Unsummetrically substituted furoxans, Part 11, methylfuroxancarbaldehydes (1989) J. Heterocycl. Chem., 26, pp. 1345-1347Gasco, A.M., Fruttero, R., Sorba, G., Gasco, A., Unsymmetrically substituted furoxans, Part XIII, phenylfuroxancarbaldehydes and related compounds (1991) Liebigs Ann. Chem., pp. 1211-1213Braman, R.S., Hendrix, S.A., Nanogram nitrite and nitrate determination in enviromental and biological materials by vanadium(III) reduction with chemiluminescence detection (1989) Anal. Chem., 61, pp. 2715-2718Castegnaro, (1978) Food Addit. Contam., 4, pp. 37-43Eakin, A.E., Mills, A.A., Harth, G., McKerrow, J.H., Craik, C.S., The sequence, organization, and expression of the major cysteine protease (cruzain) from Trypanosoma cruzi (1992) J. Biol. Chem., 267, pp. 7411-7420Li, R., Kenyon, G.L., Cohen, F.E., Chen, X., Gong, B., Dominguez, J.N., Davidson, E., McKerrow, J.H., In vitro antimalarial activity of chacones and their derivatives (1995) J. Med. Chem., 38, pp. 5031-5037Borchardt, D.M., Mascarello, A., Chiaradia, L.D., Nunes, R.J., Oliva, G., Yunes, R.A., Andricopulo, A.D., Biochemical evaluation of a series of synthetic chalcone and hydrazide derivatives as novel inhibitors of cruzain from Trypanosoma cruzi (2010) J. Braz. Chem. Soc., 21, pp. 142-150Gonçalves, J.E., Fernandes, M.B., Chiann, C., Gai, M.N., Souza, J., Storpirtis, S., Effect of pH, mucin and bovine serum on rifampicin permeability through Caco-2 cells (2012) Biopharm. Drug. Dispos., 33, pp. 316-32